Compare iShares Russell 2000 ETF (IWM) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Russell 2000 ETF vs Zimmer Biomet Holdings Inc — how do they compare? iShares Russell 2000 ETF trades at $303.05, while Zimmer Biomet Holdings Inc trades at $97.03 (market cap $18.55B). The key difference: Zimmer Biomet Holdings Inc pays a 0.99% dividend while iShares Russell 2000 ETF pays none, and iShares Russell 2000 ETF is trading nearer its 52-week high, Zimmer Biomet Holdings Inc nearer its low. Which is the better fit depends on your goals.
| IWM | ZBH | |
|---|---|---|
52-Week High | $301.69 | $107.71 |
52-Week Low | $225.45 | $79.58 |
Market Cap | — | $18.55B |
Sector | — | Health |
Enterprise Value | — | $25.61B |
Dividend Yield | — | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IWM (iShares Russell 2000 ETF) trades at $302.71, up 0.91% with a bullish technical signal from moving averages. The ETF, tracking 2,000 US small-cap stocks, shows strong institutional interest despite lacking traditional valuation ratios. Recent news highlights small-cap outperformance versus large caps, with institutional investors favoring IWM for its liquidity and options ecosystem. Technical indicators show RSI at 75 suggesting overbought conditions while ADX indicates a strong trend.
Outlook remains positive as small caps benefit from economic conditions, though high RSI suggests near-term consolidation risk. The ETF's broad small-cap exposure offers diversification but faces volatility from economic sensitivity. Institutional accumulation supports medium-term upside potential despite premium valuation concerns versus alternatives.
Zimmer Biomet (ZBH) trades at $97.9, up 0.12% on the day, with a bullish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, supported by hips, specialty businesses, and technology. Key financials show a P/E of 23.6 and net income margin of 9.48%, while cash flow from operations improved to $1.70B in 2025.
The outlook is positive, with a consensus price target of $103.56 offering ~6% upside. Risks include competitive pressures and margin volatility, but consistent earnings beats and institutional accumulation support a constructive view for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Russell 2000 ETF
The ETF is designed to track the performance of the securities and the stocks in the Russell 2000 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on IWM →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
